Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Perspective of patients with autoimmune diseases on COVID-19 vaccination.
Boekel L, Hooijberg F, van Kempen ZLE, Vogelzang EH, Tas SW, Killestein J, Nurmohamed MT, Boers M, Kuijpers TW, van Ham SM, Eftimov F, Wieske L, Rispens T, Wolbink GJ. Boekel L, et al. Among authors: killestein j. Lancet Rheumatol. 2021 Apr;3(4):e241-e243. doi: 10.1016/S2665-9913(21)00037-0. Epub 2021 Feb 22. Lancet Rheumatol. 2021. PMID: 33655220 Free PMC article. No abstract available.
Differential effect of drug interference in immunogenicity assays.
Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, Aarden LA, Rispens T. Hart MH, et al. Among authors: killestein j. J Immunol Methods. 2011 Sep 30;372(1-2):196-203. doi: 10.1016/j.jim.2011.07.019. Epub 2011 Jul 29. J Immunol Methods. 2011. PMID: 21824477
Drug interference in immunogenicity assays depends on valency.
Rispens T, Hart MH, Ooijevaar-de Heer P, van Leeuwen A, Vennegoor A, Killestein J, Wolbink GJ, van der Kleij D. Rispens T, et al. Among authors: killestein j. J Pharm Biomed Anal. 2013 Nov;85:179-85. doi: 10.1016/j.jpba.2013.07.022. Epub 2013 Jul 30. J Pharm Biomed Anal. 2013. PMID: 23954437
Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site.
van Schie KA, Kruithof S, van Schouwenburg PA, Vennegoor A, Killestein J, Wolbink G, Rispens T. van Schie KA, et al. Among authors: killestein j. J Allergy Clin Immunol. 2017 Mar;139(3):1035-1037.e6. doi: 10.1016/j.jaci.2016.09.014. Epub 2016 Oct 4. J Allergy Clin Immunol. 2017. PMID: 27717666 No abstract available.
328 results